Share Name Share Symbol Market Type Share ISIN Share Description
Omega Dia LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.15p -1.01% 14.65p 14.30p 15.00p 14.80p 14.65p 14.80p 42,263 13:50:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 13.6 -6.9 -0.4 - 18.60

Omega Diagnostics Share Discussion Threads

Showing 2651 to 2674 of 2675 messages
Chat Pages: 107  106  105  104  103  102  101  100  99  98  97  96  Older
DateSubjectAuthorDiscuss
14/9/2018
20:51
Not half empty, just a realist...I am happy that Sneller has accumulated 20% else we would be sitting at 10p...
barrywhit
14/9/2018
20:38
The salient point as far as I am concerned here is that Sneller with 20% and hopefully Mills & Co. with just over 6% are NOT selling therefore they are well on the way to collectively owning 29.9% which would be very interesting if and when this transpires. I personally couldn't care less who is offloading around these levels and as bomber13 alluded to in one of his previous posts around 15p appears to be the level where Sneller at least is happy to accumulate. Just for the record barrywhit are you by any chance a half empty type of guy?
hyperboreus
14/9/2018
20:02
The trouble is bomber, someone else is happy to sell....IF it is Sneller buying..
barrywhit
14/9/2018
18:37
I wish I had gone to the AGM , because over 1% of the equity changed hands this afternoon , and , if you look at the trades , they are predominantly buys . If it is Richard Sneller doing the buying , he is continuing to pay up , so all very encouraging .
bomber13
14/9/2018
11:52
All AGM resolutions passed - did anyone attend? Https://www.investegate.co.uk/omega-diagnostics-gp--odx-/rns/result-of-agm/201809141125328410A/
rivaldo
12/9/2018
14:49
Indeed bomber13 - I've been a patient holder of SCE for some time now. I'm more than 100% up on average there, but after recent events I suspect that there may be interesting news in the next few months. In which case Sneller's timing may be rather good.....
rivaldo
11/9/2018
23:21
Thanks for pointing that out Hyperboreous , and I now remember seeing your post last year . To the list you can also add Surface Transforms ( market cap £23m in carbon ceramics mainly for automotive ) , where Sneller cropped up with a 5.6% stake in July this year . From the names on the list so far , one can seemingly categorise his investment style as both " disruptive growth " and " value-based " , which would appear to fit Omega in spades .
bomber13
11/9/2018
15:56
Yes , you are right Rivaldo . As far as I can make out , it is by far and away his biggest personal involvement in a company as a percentage of its equity . However , he did own nearly 5% of Bango at one stage in 2017 , which would have been worth around £7m , so substantially more than his Omega stake in pure money terms . Of his previous investments , he had smallish stakes in Cryptotex and Hayward Tyler , both of which got taken over within around 6 months of his involvement , and both of which also , coincidentally , had Oryx ( Chris Miller ) as a major shareholder . You will recall in April this year when Liontrust sold its near 8% stake in Omega sub 10p , Richard Sneller took 5% and Oryx the balance , taking their holding to over 6% . Please don't get me wrong , I am not at all suggesting any collusion between the two , but both are very astute investors , sing from the same hymn sheet , which is shareholder value , and it is brilliant news for us private investors that together they now speak for over 25% of Omega .
bomber13
11/9/2018
10:08
Good summary bomber13. Sneller now has 25.43m shares, so has probably invested around £3.5m-£4m in ODX. He must be pretty convinced to tie up such a large amount in a £19m m/cap microcap!
rivaldo
10/9/2018
12:30
Thanks for spotting that barrywhit . The RNS states that the threshold of 20% was crossed or reached on Friday 7th Sept , and I note there were 2 trades amounting to 375/- shares @ around 14.5p that day , which is less than the 1% increase he has just announced . So , he has been buying for a while and , what is more , paying up , which is all highly encouraging . Going back in time to Richard Sneller's first interest in Omega , he bought his initial 10% between 2015 and 2016 at 15p to 18p a share , and , with the exception of the 5% he bought from Liontrust below 10p in April , 2018 , the 15p to 18p level is probably his average buying level over nearly 4 years . Interestingly enough , below 15p is where all the recent directors buying took place as well . So , all things being equal , 15p should therefore become the new floor whilst we await all the exciting developments we are promised over the next 2 years .
bomber13
10/9/2018
09:01
I see Richard Sneller is still confident...now 20%
barrywhit
20/8/2018
16:27
We're looking for a Regulatory Affairs Associate to join our team in Alva. The role is primarily to help us accelerate VISITECT CD4 to market, and the ideal candidate is required to have strong IVD product knowledge.
barrywhit
10/8/2018
14:13
Thanks for that bomber13 , $5 sounds about right to obtain sales This is worth a read hTTps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938542/ South Africa = Middle Income ''Conclusions This study shows that in the middle-income setting of South Africa, introduction of POC CD4 testing is likely to be cost-effective (under the threshold of GDP per capita), in comparison to existing laboratory CD4 testing, and that cost-effectiveness increases over time. CD4 counts may stop being used to assess eligibility for ART initiation in South Africa within the next couple of years; however, we found that the introduction of POC CD4 testing in the current care context was very likely to be cost-effective within one year. Moreover, CD4 testing is likely to remain a widespread tool for clinical staging of HIV positive patients before ART initiation. Given this, our findings suggest that even if ART is expanded to all HIV positive individuals in the near future, and HIV testing efforts are substantially increased, POC CD4 testing is still a cost-effective tool. Our study also illustrates the wider importance of evaluating the potential impact and cost-effectiveness of such diagnostic technologies at the population level in the future.'' and hTTp://journals.plos.org/plosone/article?id=10.1371/journal.pone.0178249 ''Conclusions Removing CD4 criteria alone will modestly increase timely uptake of ART. However, our results suggest the majority of newly-eligible patients will not initiate. Improved testing, linkage, and initiation procedures are needed to achieve 90-90-90 targets.''
buywell3
09/8/2018
12:12
According to Omega , the tests will cost around $5 each , and those HIV sufferers close to the 350 T cell margin will most likely need 2 tests per annum . Because African countries and the like cannot afford to hand out expensive retroviral drugs to all HIV sufferers , these point of care tests will determine when these drugs are needed to those without easy access to testing of their immune system . Also note on page 20 of the presentation , Omega expect the POC test to account for only half the total global testing market . The affordability question will hopefully be additionally alleviated when Omega achieves WHO accreditation ( early 2019 ? ) , thereby opening up the market to all NGO's .
bomber13
09/8/2018
11:35
My problem with ODX and CD4 is that I don't get what they are trying to do with CD4 and who their target market is ? Test kits for HIV are cheap , easy to get , and getting cheaper All persons with HIV should be started on antiretroviral treatment regardless of whether the CD4 count is high or low. So regardless of getting an ACTUAL CD4 count NUMBER , a HIV confirmed test means antiretroviral treatment should commence. I don't see for example 3rd world countries doing CD4 tests on a patient having antiretroviral treatment to plot the CD4 count every 2 weeks for example. So how much are Omega Diagnostics planning to charge for CD4 per test ? and Who do they see buying it ? I read today that Superdrug are now selling a HIV self test kit for £33.99p It works ie results are in 15mins and is 99.7% accurate There are cheaper self HIV test kits out there , here is one at £15.99 hTTps://www.chemist.co.uk/insti-hiv-self-test-kit.html another at £19.99 from bio-sure As some who read my posts have found out I like to do my own research RE CD4 ''How CD4 Counts Help Treat HIV and AIDS The CD4 count is a test that measures how many CD4 cells you have in your blood. These are a type of white blood cell, called T-cells, that move throughout your body to find and destroy bacteria, viruses, and other invading germs. Your test results help your doctor know how much damage has been done to your immune system and what's likely to happen next if antiretroviral treatment is not initiated. All persons with HIV should be started on antiretroviral treatment regardless of whether the CD4 count is high or low.'' Omega said this ''Omega remains confident in completing the verification and validation programme to deliver a unique product which will identify those people living with HIV who have advanced disease, for which there remains a significant unmet clinical need in low and middle-income countries.'' So they see their market in 3rd world and lower middle income countries They don't have much money to spend So is CD4 going to be £10 a test or less ?
buywell3
09/8/2018
10:49
Thanks for posting the investor presentation . Unfortunately , I wasn't able to go in person , but a good friend of mine did . This refreshingly open , honest and engaging approach by the management towards investors is another remarkable change in Omega's mindset , and it shows in the presentation . For the first time ever , we have been given 3 to 5 year revenue targets for the 3 remaining business segments , $19.5m for food intolerance ( a 30% share and global leadership ) , $18m for allergies ( a 10% share and note this figure has increased from the $10m assumption made at the 21st May presentation ) , and $20m for CD4 ( a 66% share of a POC market of 6m tests pa ) . Significantly , both the allergy and the CD4 numbers come from a current position of zero . From what has gone on before , and from the body language of the presenters on Monday , it is also quite clear that these numbers are being hugely risked . In CD4 for example , Omega estimates the total potential market at 6m tests pa , and assumes a 66% market share even though it will be the only point of care test available . Equally , official data for Nigeria with one of the biggest number of HIV sufferers , and Omega's No 1 target , shows only 3.2m HIV sufferers when it is widely acknowledged that the true figure may be nearer 45m , 25% of the population . The guidance for 2018/19 by Finncap , Omega's broker , and therefore their indirect mouthpiece , is also heavily risked . Estimated revenues of around £9.7m includes nothing from CD4 and next to nothing for allergies , and the net forecast is for a small loss before tax . In the 2020 year and thereafter CD4 and allergies should present a real hockey stick moment in both revenue and profits . The current year may well mean another year of base-building in the shareprice , but , with Omega now well funded to produce the growth that is promised , it may well be that the market starts to discount more and more of the potentially transformational future under this investor friendly and highly incentivised management .
bomber13
07/8/2018
14:05
Link to the Investor presentation... http://www.omegadiagnostics.com/Portals/0/ODG%20Final%20Results%20FY18%20FINAL_.pdf
barrywhit
07/8/2018
07:13
$20m sales is not bad, but what sort of margins can we expect to make on it? I imagine it's quite high.
arthur_lame_stocks
07/8/2018
06:48
Good coverage in today's Times.... Https://www.thetimes.co.uk/article/omega-puts-its-hopes-in-hiv-kits-after-posting-7m-losses-tx9qtg9gg Extract re CD4: "Mr King described the CD4 test as a “huge opportunity for us”. It measures when a patient’s white blood cell count falls below a certain level. The test has now been CE marked and distribution deals have been signed in Nigeria, Ghana, Zambia and Zimbabwe as part of a strategy to target more than 30 countries. A second version of the test is also being developed to show when cell counts fall further and the individual could be at risk of additional diseases such as tuberculosis. Mr King said that should be ready next year and Omega hopes eventually to be present in more than 130 nations by selling directly to large non-government organisations. The company believes that within the next three to five years it could be selling in the region of four million CD4 tests and generating more than $20 million revenue from them."
rivaldo
06/8/2018
16:37
Investor Evening in London tonight....may help...
barrywhit
06/8/2018
16:03
The first stage of that process was achieved on 28 June 2018 when we announced the divestment of our legacy Infectious disease business to Lab21 Healthcare Limited for GBP2.175 million. These proceeds will enable the Company to have sufficient working capital without having to either issue further equity or take on additional debt. It is intended to significantly accelerate our plans for CD4 commercialisation where the main gating item is the individual country registration. I think it is worth reflecting upon the achievement of the Omega team in being able to launch its CD4 test when a number of others have failed and expended many times what we have in the process. To date we have spent GBP2.9 million and anticipate spending a further GBP1.0 million in the coming financial year on registration activities and to complete the development of the 200-cut-off test.
barrywhit
06/8/2018
15:08
Please correct me if I am wrong BUT Supply the link/s to substantiate any argument IMO Everything will have to be sold to fund the development of CD4 re ''''The Company will use the chosen design to manufacture three validation batches which will be sent for evaluation at selected external sites including Africa and India. These evaluation results, combined with internal verification work will, if successful, enable Omega to CE--Mark the product.'' How much is the cost ? How long will it take ? A Hard Brexit re CE Mark problems which the EU seem set to make , may then add more costs that are at present not allowed for
buywell3
06/8/2018
14:09
I think the brexit negotiations have shown the true colours of the Brussels bureaucrats and yet there are still people in Britain who crave the perceived safety of running back into their arms. I still see brexit as a positive for this country. I'm all for the single market but there should have been a referendum before Major signed us up to the Maastricht Treaty back in 1992. The euro benefits Germany but shackles many other countries and political integration will continue to be a mess.
gwr7
06/8/2018
12:45
After seeing today's results I remain of the opinion that the shares are fairly valued if CD4 is a total failure and potentially very cheap if is a success. I also expect Food Intolerance to be sold in the near future which should demonstrate the value in the shares.
arthur_lame_stocks
Chat Pages: 107  106  105  104  103  102  101  100  99  98  97  96  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180924 13:05:14